Trial Profile
An Open-Label, Single-Sequence Study to Evaluate the Potential CYP 3A4 Pharmacokinetic Interaction of GW876008 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Emicerfont (Primary) ; Midazolam
- Indications Anxiety disorders; Depressive disorders
- Focus Pharmacokinetics
- Sponsors GSK
- 24 Mar 2009 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 22 Jun 2007 Status change from recruiting to completed
- 10 Feb 2007 New trial record.